Vepdegestrant (ARV-471)(Arvinas, Inc.) · Jun 5, 2026 NDA+Camizestrant(AstraZeneca PLC) · Jun 15, 2026 NDA
ER+/HER2- advanced breast cancer with ESR1 mutations — same indication, same month, two completely different ways to attack the estrogen receptor.
Vepdegestrant (Arvinas/Pfizer) is the first PROTAC ever to reach an FDA decision: a degrader that drags ER to the cell's protein-disposal machinery. Camizestrant (AstraZeneca) is a next-generation oral SERD: an antagonist that binds ER and triggers its degradation by a different route. Both ran their Phase 3 trials (VERITAC-2, SERENA-6) against fulvestrant — the intramuscular SERD that's been standard for ESR1-mutated patients since 2002. Two different molecules, same target, same comparator, ten days apart. The longer question: which mechanism holds up better as patients cycle through endocrine resistance.
See also: Thalidomide Accidentally Invented Targeted Protein Degradation
Baxdrostat(AstraZeneca PLC) · Jun 15, 2026 NDAPriority ReviewBreakthrough
Hard-to-control hypertension — blood pressure that stays high despite three or more standard medications.
Baxdrostat is the first aldosterone synthase inhibitor ever submitted to the FDA. About 10% of treated hypertensive patients can't get to target on standard ACEi/ARB/diuretic combinations — those regimens block the downstream effects of aldosterone, never the source. Baxdrostat shuts down aldosterone production itself. AstraZeneca ran the BaxHTN Phase 3 trial and earned Breakthrough, Fast Track, and Priority Review on its strength. If the label covers resistant hypertension broadly, the addressable population runs into the tens of millions of US adults.
Cytisinicline(Achieve Life Sciences, Inc.) · Jun 20, 2026 NDABreakthrough
Smoking cessation — first new pharmacotherapy mechanism for nicotine dependence in two decades.
Cytisinicline is a plant-derived alkaloid that's been used in Eastern Europe as Tabex since the 1960s but never approved in the US. It binds the same α4β2 nicotinic acetylcholine receptor as varenicline (Chantix, approved 2006) but with a different chemistry that ORCA-2 and ORCA-3 — Achieve's two Phase 3 trials totaling more than 2,000 patients — suggest is better tolerated. Smoking still drives roughly 480,000 US deaths a year. No new mechanism has launched since varenicline, which itself was off the market 2021-2024 over nitrosamine contamination. Watch the label for neuropsychiatric warning language.
veligrotug(Viridian Therapeutics, Inc.\DE) · Jun 30, 2026
Thyroid eye disease — bulging eyes, double vision, and pain caused by autoimmune inflammation behind the eye.
Veligrotug is an IGF-1R-blocking antibody, the same target mechanism as the only currently approved TED therapy. For Viridian, this would be the company's first commercial product — a $2B market that's had one drug serving it for six years. The Phase 3 THRIVE trial is the basis for the BLA. Two things to watch on approval: the rate of permanent hearing loss listed in the label (the existing TED therapy carries a boxed warning), and the infusion-cycle length (the standard regimen today is eight IV infusions over 24 weeks).
See also: IGF-1R: 20 Years of Cancer Failures, Then a $2 Billion Eye Drug
